Meet Eric Robertson, Director, Clinical Compliance. Eric helps ensure that our clinical trials adhere to international guidelines that guarantee quality, safety and integrity. Eric and his team embody the Tango values of “urgency” and “resilience” as they navigate the world of compliance and risk, as he notes: “Every day my colleagues and I are trouble shooting something unique.” Through collaboration with multiple stakeholders, interpreting and applying health agency regulations and guidance and making sure we have robust documentation, Eric and his team are at the helm overseeing that our clinical trials operate at the highest quality.
Tango Therapeutics
Biotechnology Research
Boston, Massachusetts 15,579 followers
Targeting tumor suppressor loss to unmask vulnerabilities for the next generation of precision medicines.
About us
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
- Website
-
https://www.tangotx.com/
External link for Tango Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Public Company
- Founded
- 2017
- Specialties
- cancer, pharmaceutical research, functional genomics, drug discovery, and synthetic lethality
Locations
-
Primary
201 Brookline Ave
Suite 901
Boston, Massachusetts 02215, US
Employees at Tango Therapeutics
Updates
-
Demonstrating our values of courage, spirit and resilience, 22 Tango associates (with no prior experience) took to the Charles River for the 46th Boston Hong Kong Dragon Boat Festival. Led by team captain Ashley Bui, Team Tango had an impressive performance and most importantly, took part in a cultural tradition celebrated worldwide and meaningful to many associates at Tango. shangtao liu, Yi Yu, Wenhai Zhang, Sirimas Sudsakorn, Alvin Lu, Ruolan L., Alvaro Amor, Kasia Handing, Simon Liang, Ben-Oni Jean-Pierre, Hana McMurtray, Deep Patel, Mu-Sen Liu, Peter Murphy, Matthew Tonini, Hilary Nicholson, Minjie Z., Steven Lombardo, Vivian Du, Jacob McAllister, Anna Chen
-
At Tango, we support and foster an environment where we embrace our differences. Throughout June, associates celebrated #PrideMonth through ribbon making and learning about colleagues who are part of the LGBTQ+ community as well as historic LGBTQ+ events. We closed out the month with an associate-led lunch and learn about the history and importance of #PrideMonth over barbeque from Sweet Cheeks Q, a local LGBTQ+ owned restaurant. We are committed to creating a strong, dynamic and equitable community where associates can bring their authentic selves to work, every day.
-
-
Join us this afternoon as Barbara Weber, M.D., President and CEO, presents at the Goldman Sachs 45th Annual Global Healthcare Conference. Learn more: https://lnkd.in/eMGwe8_V
-
-
At Tango, learning and development is deeply embedded and encouraged in our culture. Our monthly “TangoTalk” sessions provide non-scientists with 101 sessions ranging from understanding the basics of computational chemistry to clinical biomarkers. Drew Sansone, Chief Regulatory Officer, recently provided an overview into the role of Drug Regulatory Affairs and the lifecycle of a drug given his more than 25 years in the industry. His talk and the Q&A discussion that followed provided associates with an understanding of the regulatory process and the potential path of our clinical-stage precision oncology programs.
-
-
Meet one of the newest members of the Tango team, Julie Carretero, who joins in the new role of Chief Human Resources Officer. Julie brings over 25 years of biopharmaceutical and human resources experience. Most recently, she served as Chief People Officer at Evelo Biosciences where she oversaw growth from a clinical to a commercial-stage company. Previously she held senior human resources roles at multiple companies including FXI, Matter Communications and Novartis. Read more, here: https://lnkd.in/dKC47Ddq
-
-
Meet Suleman Hussain, Ph.D., Translational Scientist. At Tango, Suleman is the clinical biomarker lead for two of our clinical-stage precision oncology programs, working with the clinical team to assist with patient eligibility and collaborating with discovery biology to link preclinical research to the clinical results. With so much cross-functionality, it’s no wonder he enjoys the dynamic nature of his role. As he states, “one of things I enjoy most about my job is that every week I never know what the new challenge is going to be.”
-
-
$TNGX news: Today we announced 1Q earnings and recent business updates, including advancing our two PRMT5 molecules into dose expansion, continuing progress in the phase 1/2 clinical trials of TNG260 and TNG348, and welcoming the newest member of our leadership team, Julie Carretero as Chief Human Resources Officer. Read the full announcement here: https://lnkd.in/dKC47Ddq
-
-
Meet Colin Liang, Director, Process Chemistry. At Tango, Colin helps to develop chemical processes for production and manufacturing of drug substance – a busy job given we have four ongoing clinical trials. Each clinical compound requires multi-step synthesis and high quality. By implementing innovative chemistry, route design and process optimization, Colin’s team successfully delivered multi-kilograms of TNG348. These kilograms of material allowed for the submission and IND clearance for TNG348 as it advanced into a phase 1/2 clinical trial.
-